Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm – 2020 Executive Summary

医学 以兹提米比 内科学 烟酸 血脂异常 他汀类 类降脂药 内分泌学 疾病 糖尿病 动脉粥样硬化性心血管疾病 胃肠病学
作者
Yehuda Handelsman,Paul S. Jellinger,Chris Guerin,Zachary T. Bloomgarden,Eliot A. Brinton,Matthew J. Budoff,Michael H. Davidson,Daniel Einhorn,Sergio Fazio,Vivian Fonseca,Alan J. Garber,George Grunberger,Ronald M. Krauss,Jeffrey I. Mechanick,Paul D. Rosenblit,Donald A. Smith,Kathleen Wyne
出处
期刊:Endocrine Practice [Elsevier]
卷期号:26 (10): 1196-1224 被引量:182
标识
DOI:10.4158/cs-2020-0490
摘要

The treatment of lipid disorders begins with lifestyle therapy to improve nutrition, physical activity, weight, and other factors that affect lipids. Secondary causes of lipid disorders should be addressed, and pharmacologic therapy initiated based on a patient’s risk for atherosclerotic cardiovascular disease (ASCVD). Patients at extreme ASCVD risk should be treated with high-intensity statin therapy to achieve a goal low-density lipoprotein cholesterol (LDL-C) of <55 mg/dL, and those at very high ASCVD risk should be treated to achieve LDL-C <70 mg/dL. Treatment for moderate and high ASCVD risk patients may begin with a moderate-intensity statin to achieve an LDL-C <100 mg/dL, while the LDL-C goal is <130 mg/dL for those at low risk. In all cases, treatment should be intensified, including the addition of other LDL-C-lowering agents (i.e., proprotein convertase subtilisin/kexin type 9 inhibitors, ezetimibe, colesevelam, or bempedoic acid) as needed to achieve treatment goals. When targeting triglyceride levels, the desirable goal is <150 mg/dL. Statin therapy should be combined with a fibrate, prescription-grade omega-3 fatty acid, and/or niacin to reduce triglycerides in all patients with triglycerides ≥500 mg/dL, and icosapent ethyl should be added to a statin in any patient with established ASCVD or diabetes with ≥2 ASCVD risk factors and triglycerides between 135 and 499 mg/dL to prevent ASCVD events. Management of additional risk factors such as elevated lipoprotein(a) and statin intolerance is also described.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
hutian完成签到,获得积分10
刚刚
刚刚
botanist完成签到 ,获得积分10
1秒前
1秒前
2秒前
lihai1完成签到,获得积分10
2秒前
3秒前
3秒前
4秒前
太叔夜南发布了新的文献求助10
5秒前
MrX发布了新的文献求助10
6秒前
8秒前
TiY发布了新的文献求助10
8秒前
8秒前
9秒前
HYCT发布了新的文献求助10
9秒前
杜晓雯完成签到,获得积分10
9秒前
bioglia发布了新的文献求助50
10秒前
www发布了新的文献求助10
10秒前
小叙发布了新的文献求助10
10秒前
11秒前
11秒前
满意紫菜发布了新的文献求助10
12秒前
小蘑菇应助zlp采纳,获得10
12秒前
吃不饱星球球长应助小张采纳,获得150
12秒前
傲慢与偏见zz应助SevenKing采纳,获得10
13秒前
机灵柚子发布了新的文献求助20
14秒前
金容发布了新的文献求助10
14秒前
123发布了新的文献求助10
15秒前
未白镇常客完成签到,获得积分20
16秒前
一只熊发布了新的文献求助10
17秒前
17秒前
yy应助研友_LOoomL采纳,获得10
18秒前
完美世界应助幸运海星采纳,获得10
18秒前
华仔应助幸运海星采纳,获得30
18秒前
19秒前
NexusExplorer应助Sunziy采纳,获得10
19秒前
20秒前
高分求助中
歯科矯正学 第7版(或第5版) 1004
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Semiconductor Process Reliability in Practice 720
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 700
Mesopotamian divination texts : conversing with the gods : sources from the first millennium BCE 500
Days of Transition. The Parsi Death Rituals(2011) 500
The Heath Anthology of American Literature: Early Nineteenth Century 1800 - 1865 Vol. B 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3223177
求助须知:如何正确求助?哪些是违规求助? 2871898
关于积分的说明 8177369
捐赠科研通 2538751
什么是DOI,文献DOI怎么找? 1370791
科研通“疑难数据库(出版商)”最低求助积分说明 645870
邀请新用户注册赠送积分活动 619844